Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
12 Results for "
substrate-binding domain
" in MedChemExpress (MCE) Product Catalog:
Products (12)
12 Results for "substrate-binding domain" in MCE Product Catalog:
Cat. No.: HY-168437
LIN28-IN-2 is a Lin28 inhibitor with activity against Lin28a, Lin28b, and their zinc knuckle domain. LIN28-IN-2 blocks Lin28-RNA substrate binding, perturbs zinc knuckle domain conformation. LIN28-IN-2 inhibits cancer cell proliferation, spheroid growth, and induces G2/M phase arrest. LIN28-IN-2 suppresses cancer stem cell phenotypes, Lin28-mediated stress granule formation, let-7 target genes, cancer stem cell biomarkers, and neuroendocrine biomarkers expression in cancer cells. LIN28-IN-2 can be used for the research of cancer .
Cat. No.: HY-122184
CAS No.: 34387-64-9
PET-16 is a selective HSP70 inhibitor that binds to an allosteric pocket of the substrate-binding domain. PET-16 inhibits the ability of HSP70 to cycle between ATP-bound and ADP-bound states. PET-16 induces apoptosis in multiple myeloma .
Cat. No.: HY-157558
Synonyms: 8SGE
Target:
Research Areas:
KDRLKZ-1 (8SGE) is a small-molecule ligand of KLHDC2 E3 ligase (Kd = 0.36 μM), with an IC50 of 0.21 μM and 0.31 μM in alphaLISA and TR-FRET assays, respectively. KDRLKZ-1 binds to the substrate-binding pocket of the KLHDC2 kelch domain, mimics the interaction of natural substrates and displaces them. KDRLKZ-1 acts as an oligomer disruptor, regulates the oligomerization of the KLHDC2-EloB-EloC complex, and induces the dissociation of tetramers into smaller components. KDRLKZ-1 can be used in scaffold ligand research for PROTAC degraders targeting KLHDC2 .
Cat. No.: HY-P3892
CAS No.: 309247-48-1
Target:
Research Areas:
Cat. No.: HY-P11080
CAS No.: 1235497-90-1
Cat. No.: HY-157559
Target:
Research Areas:
KDRLKZ-2 is a small-molecule ligand of KLHDC2 E3 ligase (Kd = 95 nM), with an IC50 of 68 nM and 0.1 μM in alphaLISA and TR-FRET assays, respectively. KDRLKZ-2 binds to the substrate-binding pocket of the kelch domain of KLHDC2, mimics the interaction of natural substrates and displaces them. KDRLKZ-2 acts as an oligomer disruptor, regulates the oligomerization of the KLHDC2-EloB-EloC complex, and induces the dissociation of tetramers into smaller components. KDRLKZ-2 can be used in scaffold ligand studies of PROTAC degraders targeting KLHDC2 .
Cat. No.: HY-183406
CAS No.: 102616-62-6
Research Areas:
AS15 is a PDIA1 inhibitor with an IC50 value of 300 nM. AS15 interacts with the active-site cysteine of PDIA1, and this process is independent of the substrate-binding domain of PDIA1. AS15 acts as a synergistic cell growth inhibitor with buthionine sulfoximine (BSO) (HY-106376), a glutathione synthesis inhibitor. AS15 can be used in the research of glioblastoma .
Cat. No.: HY-P6300
CAS No.: 169062-92-4
Cat. No.: HY-P11620
CAS No.: 290810-63-8
Target:
Research Areas:
Cat. No.: HY-181810
CAS No.: 2215779-34-1
EG36 is a selective E. coli DnaK inhibitor that inhibits DnaK ATPase activity at a concentration of 100 μM. EG36 directly binds to the nucleotide-binding domain (NBD) of E. coli DnaK by disrupting the DnaK-DnaJ interaction. EG36 can be used for research on bacterial infectious diseases .
Cat. No.: HY-182372
CAS No.: 1638153-78-2
Target:
Research Areas:
SH-11037 is a potent inhibitor of soluble epoxide hydrolase (sEH) and docks to the substrate binding cleft in the sEH hydrolase domain. SH-11037 dose-dependently suppresses angiogenesis in the choroidal sprouting assay ex vivo and inhibited ocular developmental angiogenesis in zebrafish larvae. SH-11037 reduces choroidal neovascularisation lesion volume in the laser-induced CNV mouse model. SH-11037 synergises with anti-VEGF treatments in vitro and in vivo. SH-11037 induces G2/M phase blockade and retains retinal endothelial cell viability at active concentrations without overt toxicity. SH-11037 can be used for the research of retinal neovascularization and ocular neovascularization .
Cat. No.: HY-138934
CAS No.: 1642375-66-3
Target:
Research Areas:
Bepristat 1a is a reversible, selective protein disulfide isomerase (PDI) inhibitor with an IC50 of 0.7 μM. Bepristat 1a inhibits platelet aggregation in laser-injured mouse arterioles. Bepristat 1a is applicable for research related to thrombosis .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
